Janux Therapeutics (JANX) Other Accumulated Expenses (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Other Accumulated Expenses data on file, last reported at $841000.0 in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses fell 9.08% year-over-year to $841000.0 in Q1 2026; TTM through Mar 2026 was $841000.0, a 9.08% decrease from a year earlier, with the FY2025 full-year figure at $944000.0, up 2.83% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $841000.0, down from $944000.0 in the prior quarter.
• Over the last five years, Other Accumulated Expenses for JANX reached as high as $1.0 million in Q2 2023 and fell as low as $332000.0 in Q1 2022.
• Historically, Other Accumulated Expenses has averaged $699529.4 across 5 years, with a median of $718000.0 in 2024.
• Across the five-year window, Other Accumulated Expenses jumped 194.52% in 2023 and slipped 29.75% in 2024, its largest moves.
• Year by year, Other Accumulated Expenses stood at $623000.0 in 2022, then dropped by 11.88% to $549000.0 in 2023, then surged by 67.21% to $918000.0 in 2024, then increased by 2.83% to $944000.0 in 2025, then slipped by 10.91% to $841000.0 in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $841000.0 in Q1 2026, $944000.0 in Q4 2025, and $551000.0 in Q3 2025.